Any rapamycin questions to ask Matt Kaeberlein?

#46

What is the name of your podcast? I want to be able to find it on Spotify

2 Likes
#47

Mikhail changed his dose from biweekly to weekly awhile ago so Matt Kaeberlein and Mikhail Blagosklonny is taking the same dose. Matt is just cycling with off and on periods also. Check the image I attached :pray:

1 Like
#48

You can search for Rapamycin Master Series. Here is an link to podcast in Spotify

2 Likes
#49

If Rapamycin blocks mTOR complex 1, why adding Acarbose make the treatment even more effective? (What role does Acarbose play and is it independent from blocking mTOR or helping Rapamycin and how?)

2 Likes
#50

FWIW

That question should be asked to the person that was the lead researcher on the experiment/paper published.

I think that was Richard Miller?

1 Like
#51

I’ve heard it boosts mtor complex 2, so if Rapa pulls down 2 a bit, then maybe acarbose helps boost it back up?

It helps starch make it through the gut to the colon where it can be made into short chain fatty acids. These are thought to be good. Also this helps reduce long term blood sugar. And SCFA also activate GLP-1, we learned recently, so that could help control blood sugar too.

2 Likes
#52

Are there any health conditions in senior dogs that would preclude them from taking Rapamycin? For example, kidney and liver disease are common in senior dogs, so would Rapamycin help or harm senior dogs with those diseases? Are there any dosing updates that would replace the .1mg/kg MWF dosing schedule?

2 Likes
#53

Please ask if using rapa has downsides for folks with osteoarthritis, based on this study with guinea pigs that made arthritis worse, along with raising glucose - though dosing was continuous, not weekly. Rapamycin-induced hyperglycemia is associated with exacerbated age-related osteoarthritis - PMC

3 Likes
#54

This article about blood pressure med rilmenidine, showing it’s an alternate way to inhibit mTOR, has gotten a lot of attention for possible lifespan extension, any comment from Matt? Will it be evaluated via the ITP study with mice? https://onlinelibrary.wiley.com/doi/10.1111/acel.13774

1 Like
#55

What would be the 42ppm dose done in mice with 26% lifespan extension in dogs/humans?

1 Like
#56

Yes: please ask this! And so he doesn’t have to answer it off the cuff, please send him the paper in advance, and to head off what may be his off-the-cuff response, please point out that while there are previous studies that found rapa or genetic mTOR inhibition to be protective against surgically-induced OA in young mice, this is the first study in primary, age-related OA.

2 Likes
#57

See this handy if depressing table from our intrepid administrator:

1 Like
#58

I had the interview with Matt this Thursday and we talked around 2,5 hours and I needed to cut out lot of questions also otherwise it would have been 5 hours :sweat_smile: But we will do a second interview in the future. So just add more potential questions here in this discussion thread and I will take a look next time which has been covered and not :pray:

8 Likes
#59

Fantastic! We are eagerly awaiting your podcast.

2 Likes
#60

Did you get the osteoarthritis question in?

1 Like
#61

Sorry, not this time…

1 Like
#62

Thanks Krister. Any sense when podcast may go live?

1 Like
#63

My goal is to be completed with editing, creating slides and other things around Alan Green’s interview soon so that I can publish that interview next week. After that I will start editing the Matt Kaeberlein’s interview and also preparing for the next guest in the podcast. So there are many todos to keep the ball rolling :slight_smile:

6 Likes
#64

Got it, thx for update. Look forward to it.

1 Like
#65

Do you have a point of view on effectiveness of Rapamycin and Rilmenidine in combination?

1 Like